[Featured Stock] Synergy Innovation, Investor Anticipates Fundamental Treatment for Stroke Sequelae

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation recorded a limit-up. The news that domestic researchers have uncovered the mechanism behind the occurrence of 'functional dissociation,' which causes various sequelae such as language disorders after stroke caused by blocked or ruptured brain blood vessels, appears to have influenced the stock price.

As of 10:17 a.m. on the 8th, Synergy Innovation was trading at 2,155 KRW, up 29.82% (495 KRW) compared to the previous trading day.

Changjun Lee, head of the Cognitive and Sociality Research Group at the Institute for Basic Science (IBS), and Hyungil Kim, professor of Biomedical Engineering at Gwangju Institute of Science and Technology (GIST), announced the day before that they identified abnormal changes in 'astrocytes' as a key factor in functional dissociation occurring after stroke, which was introduced in the international academic journal Cell Reports.

The research team also confirmed the efficacy of the MAO-B inhibitor KDS2010, which they developed and licensed to Neurobiogen. As a result of administering the inhibitor, GABA secretion decreased, alleviating functional dissociation in the motor cortex and restoring motor and sensory functions. This clarified the principle of alleviating functional dissociation by suppressing GABA production through astrocyte regulation, while experimentally proving the efficacy of their self-developed therapeutic agent.

Professor Hyungil Kim stated, "We have unlocked the mystery of functional dissociation and presented one of the first treatment methods for neurological diseases including stroke," adding, "This will serve as a new benchmark for developing treatments for various neurological brain diseases accompanied by functional dissociation."

Director Changjun Lee explained, "This research identified the mechanism inducing functional dissociation associated not only with stroke but also with various brain diseases such as migraine, brain tumors, and encephalitis," and added, "We expect that astrocyte regulation will open new paths for treating sequelae of various brain diseases in the future."

Synergy Innovation, a bio and medical device specialized company, invested in Neurobiogen's convertible bonds (CB) last November to establish a new drug development pipeline and secure new growth engines. Upon conversion of the CB, it will secure the status of the largest shareholder.